Anti-Cancer Compounds: The invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like.
By acting on different combinations of Cyclin Dependent Kinases it is possible to stop normal cells growing or to cause cancer cells to commit suicide, otherwise known as apoptosis.
Seliciclib is an orally available cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets that are central to the process of cell division and cell cycle control.
The Company is currently evaluating seliciclib (CYC202), an orally available cyclin dependent kinase inhibitor, in Phase II clinical trials for the treatment of lung cancer.
Seliciclib is an orally available
cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control.
Mitotix will use this technology to develop new therapeutic products for the treatment of cancer and other cell proliferation disorders in its drug discovery program focused on
cyclin dependent kinase inhibitors.
Paracelsian's patented CDK assays measure the concentration of at least one
cyclin dependent kinase in the blood, plasma or serum of an animal or human, and correlates that concentration to the presence of abnormal cellular proliferation or tumor development in any tissue of the organism from which the sample was obtained.
